ONL Therapeutics reports positive phase 1b data for xelafaslatide in GA | Optometry Times - Clinical News

Published on December 11, 2025
Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death.
Continue reading on website
Other news

Hat-trick for Monnow Eyecare at Optometry Wales Awards after major flood destroys practice

December 11, 2025
The Monmouth practice is facing temporary relocation to Monmouth Business Park after experiencing severe flood damage and the loss of all consulting rooms

Optical Women’s Association Announces 2025 Leadership Scholarship Winners

December 12, 2025
DALLAS—The Optical Women’s Association (OWA) has announced the awardees for its 2025 Leadership Scholarship. Recipients are recognized as OWA members who have served the organization with their dedicated committee work, service and commitment to growing leadership roles for women in the optical industry, the OWA said. Winners receive grants valued at up to $2,000 each, which will be used to provid